Drug Trial Radar · NCT02691299
A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Feb 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
527
Actual
Start
Dec 9, 2015
Primary completion
Sep 21, 2018
Study completion Nov 16, 2018
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fruquintinib/Placebo 5 mg, QD, orally administered under fasting conditions for 3 consecutive weeks followed by one-week off to evaluate the survival benefit of patients with advanced non-squamous NSCLC treated with Fruquintinib.
Conditions
- NSCLC
Interventions
FruquintinibDrug
Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
PlaceboDrug
Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Primary outcomes
What the sponsor says the trial is designed to measure.
- overall survival (OS)Time frame: From the date of randomization until the date of death from any cause, Assessed up to 15 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
307 Hospital of PLA
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital
Beijing, Beijing Municipality, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Nantong Tumor Hospital
Nantong, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
Linyi Tumor Hospital
Linyi, Shandong, China
The Cancer Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
West China Hospital
Chengdu, Sichuan, China
The First Affiliated Hosptial of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.